Moreover, in murine RCC xenografts, axitinib augments CD8+ T cell-mediated antitumor activity against renal carcinoma via a STAT3-dependent reversal of myeloid suppressor cells (MDSC) accumulation in the spleens and tumor beds [17]. Here, STAT3 is linked to renal cell carcinoma.